Detail akcie Neuronetics Rg online

Business Summary: Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Neuronetics Inc revenues increased from $52.4M to $107.4M. Net loss increased 3% to $31.8M. Revenues reflect United States segment increase from $50.8M to $105.4M, International segment increase of 28% to $2M. Higher net loss reflects Medical Equipment, Supplies & Distribution segment loss increase of 14% to $26.4M.